Alexandra’s practice focuses primarily on the life sciences sector, advising biotechnology, pharmaceutical and medical technology companies in a wide range of transactions, many of which have a significant international element.
Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion
December 20, 2022
A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.
